[1]孙来顺.氨磺必利与利培酮治疗精神分裂症阴性症状的疗效比较[J].医学信息,2022,35(07):121-123.[doi:10.3969/j.issn.1006-1959.2022.07.030]
　SUN Lai-shun.Comparison of Therapeutic Effects of Amisulpride and Risperidone on Negative Symptoms of Schizophrenia[J].Medical Information,2022,35(07):121-123.[doi:10.3969/j.issn.1006-1959.2022.07.030]
点击复制

氨磺必利与利培酮治疗精神分裂症阴性症状的疗效比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年07期
页码:
121-123
栏目:
论著
出版日期:
2022-04-01

文章信息/Info

Title:
Comparison of Therapeutic Effects of Amisulpride and Risperidone on Negative Symptoms of Schizophrenia
文章编号:
1006-1959（2022）07-0121-03
作者:
孙来顺
（天津市宝坻区安康医院精神科，天津 301800）
Author(s):
SUN Lai-shun
(Department of psychiatry,Ankang Hospital,Baodi District,Tianjin 301800,China)
关键词:
精神分裂症; 阴性症状; 不良反应; 氨磺必利; 利培酮
Keywords:
Schizophrenia; Negative symptoms; Adverse reactions; Amisulpride; Risperidone
分类号:
R749.3
DOI:
10.3969/j.issn.1006-1959.2022.07.030
文献标志码:
A
摘要:
目的 比较氨磺必利与利培酮治疗精神分裂症阴性症状的临床疗效。方法 选取2019年5月-2021年5月天津市宝坻区安康医院精神科收治的72例精神分裂症阴性症状患者，采用随机数字表法分为氨磺必利组和利培酮组，每组36例。氨磺必利组给予氨磺必利治疗，利培酮组给予利培酮治疗。比较两组阳性和阴性症状量表（PANSS）评分、阴性症状量表（SANS）评分、临床疗效与不良反应发生率。结果 氨磺必利组PANSS评分、SANS量表中意志缺乏评分及兴趣社交缺乏评分低于利培酮组，差异有统计学意义（P＜0.05）；氨磺必利组治疗总有效率与利培酮组比较，差异无统计学意义（P＞0.05），但氨磺必利组阴性治疗有效率高于利培酮组，差异有统计学意义（P＜0.05）；氨磺必利组不良反应发生率为22.22%，低于利培酮组的47.22%，差异有统计学意义（P＜0.05）。结论 氨磺必利与利培酮治疗精神分裂症疗效相当，但前者阴性疗效更为显著，可有效改善患者意志障碍及社交兴趣障碍，且安全性更高。
Abstract:
Objective To compare the clinical efficacy and adverse reactions of amisulpride and risperidone in the treatment of negative symptoms of schizophrenia.Methods A total of 72 patients with negative symptoms of schizophrenia admitted to the Department of Psychiatry of Ankang Hospital, Baodi District, Tianjin from May 2019 to May 2021 were selected and randomly divided into amisulpride group and risperidone group, with 36 cases in each group. Amisulpride group was treated with amisulpride, and risperidone group was treated with risperidone. PANSS score, SANS score, clinical efficacy and incidence of adverse reactions were compared between the two groups.Results The PANSS score, the SANS scale score of will deficiency and the score of interest and social deficiency in the amisulpride group were lower than those in the risperidone group, and the difference was statistically significant (P<0.05). There was no significant difference in the total effective rate between the amisulpride group and the risperidone group (P>0.05), but the negative effective rate of the amisulpride group was higher than that of the risperidone group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the amisulpride group was 22.22%, which was lower than 47.22% in the risperidone group, and the difference was statistically significant (P<0.05).Conclusion Amisulpride and risperidone have the same curative effect in the treatment of schizophrenia, the negative effect of the former is more obvious, which can effectively improve the patients’ will disorder and social interest disorder, and the safety is higher.

参考文献/References:

[1]穆小梅,王秀梅,牛慧明,等.氨磺必利治疗阴性症状精神分裂症的临床疗效[J].甘肃医药,2021,40(5):410-412.[2]Leweke FM,Rohleder C,Gerth CW,et al.Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial[J].Front Pharmacol,2021(12):614811.[3]Carli M,Kolachalam S,Longoni B,et al.Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences[J].Pharmaceuticals (Basel),2021,14(3):238.[4]李洪成.氨磺必利与利培酮治疗老年期精神分裂症疗效及安全性比较研究[J]. 齐齐哈尔医学院学报,2017,38(14):1640-1641.[5]张欣,桂敏.氯氮平、奥氮平与利培酮对精神分裂症患者肾功能的影响对比研究[J].吉林医学,2019,40(3):553-554.[6]中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.[7]Lin CH,Lin CH,Chang YC,et al.Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial[J].Biol Psychiatry,2018,84(6):422-432.[8]崔彦龙,严保平,孙秀丽,等.氨磺必利与利培酮治疗阴性症状为主精神分裂症疗效及安全性对照研究[J].医学研究与教育,2018,35(6):42-47.[9]廖国栋,蒙雪芳,蓝超越,等.氨磺必利和利培酮治疗女性精神分裂症的效果及对患者糖脂代谢指标的影响[J].中国医药科学,2020,10(1):81-84.[10]邬俊福,彭红波,张运才.氨磺必利与利培酮治疗精神分裂症疗效及对患者血清PRL和CRP水平的影响[J].临床心身疾病杂志,2019,25(2):29-32.[11]李庆梅,李娜,蔡雪梅.氨磺必利与利培酮在女性首发精神分裂症患者认知功能中的疗效分析[J].中国卫生标准管理,2018,9(2):89-90.[12]韩勇,姜涛.氨磺必利与利培酮对精神分裂症患者血清泌乳素水平的影响[J].山东医药,2016,56(2):88-89.[13]马春红.氨磺必利与利培酮治疗精神分裂症对照研究[J].中国实用神经疾病杂志,2015(13):121-122.[14]俞波,赵俊雄,施波,等.利培酮对首发和慢性精神分裂症患者惊跳反射弱刺激抑制和P50的影响[J].中华医学杂志,2020,100(36):2841-2845.[15]詹同宝.氨磺必利与利培酮治疗首发精神分裂症临床效果比较[J].中国基层医药,2017,24(5):743-746.[16]于晓东,季加翠,林正华,等.氨磺必利与利培酮治疗伴抑郁症状的精神分裂症对照研究[J].精神医学杂志,2016,29(4):277-279.[17]邓良华,许世欢,徐健.氨磺必利治疗首次发病的精神分裂症患者的随机对照研究[J].临床精神医学杂志,2016,26(4):248-250.

相似文献/References:

[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
　ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Medical Information,2018,31(07):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
　ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Medical Information,2018,31(07):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症 疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
　SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Medical Information,2018,31(07):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
　SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Medical Information,2022,35(07):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
[5]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
　SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Medical Information,2018,31(07):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[6]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
　WU Jin-li.Clinical Application of Aripiprazole[J].Medical Information,2018,31(07):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
[7]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
　SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Medical Information,2018,31(07):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[8]凌 梅,刘静芳.精神分裂症患者研究伙伴的相关研究进展[J].医学信息,2018,31(19):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
　LING Mei,LIU Jing-fang.Progress in Research on Research Partners in Patients with Schizophrenia[J].Medical Information,2018,31(07):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
[9]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
　HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Medical Information,2018,31(07):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[10]陈宽玉,孔 骞,黄玉桃.首发缓解期精神分裂症患者日常生活模式的调查[J].医学信息,2019,32(04):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
　CHEN Kuan-yu,KONG Qian,HUANG Yu-tao.Investigation on the Daily Life Pattern of Patients with Schizophrenia in the First Remission Period[J].Medical Information,2019,32(07):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
[11]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
　CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Medical Information,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[12]孙来顺.氨磺必利治疗阴性症状为主的精神分裂症患者的疗效[J].医学信息,2021,34(22):136.[doi:10.3969/j.issn.1006-1959.2021.22.042]
　SUN Lai-shun.Efficacy of Amisulpride in the Treatment of Schizophrenia Patients with Negative Symptoms[J].Medical Information,2021,34(07):136.[doi:10.3969/j.issn.1006-1959.2021.22.042]
[13]王 震.氯氮平与氯丙嗪治疗维持期精神分裂症患者的临床疗效及安全性比较[J].医学信息,2023,36(03):152.[doi:10.3969/j.issn.1006-1959.2023.03.032]
　WANG Zhen.Comparison of Clinical Efficacy and Safety of Clozapine and Chlorpromazine in the Treatment of Patients with Maintenance Schizophrenia[J].Medical Information,2023,36(07):152.[doi:10.3969/j.issn.1006-1959.2023.03.032]

更新日期/Last Update: 1900-01-01